Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $31M (up 19.9% year over year) with net income of $6M.
Q3 2025 key financials · XBRL
- Revenue
- $31M
- +19.9% YoY · +14.2% QoQ
- Net income
- $6M
- +110.7% YoY · +276.8% QoQ
- Operating margin
- 22.7%
- Gross margin
- 94.7%
- EPS (diluted)
- $0.03
- +200.0% YoY · +200.0% QoQ
Source: XBRL data from the GYRE THERAPEUTICS, INC. (GYRE) Q3 2025 10-Q on SEC EDGAR. USD.
GYRE THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 2025 pirfenidone trial completed patient enrollment; Etorel® launched commercially in Q2 2025
- Hydronidone Phase 3 met primary endpoint, with fibrosis regression significance at P=0.0002
- Hydronidone serious adverse events 4.88% vs 6.45% placebo
- Hydronidone NMPA New Drug Application submission ongoing
- Hydronidone U.S. IND filing planned for 2026, subject to regulatory feedback
Risk Factors
- No material changes from Annual Report risk factors
- Carried-forward risks potentially affecting business, financial position, and future operating results
- Additional unknown or currently immaterial risks could materially adversely affect results
- Executive-linked trading arrangement covering potential sale of up to 700,000 shares
- Rule 10b5-1 arrangement terminates within 15 months or after all shares are sold
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GYRE THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.